I SAY DUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUMPO !!
Recent ALLR News
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:54:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:15:26 PM
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 08:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:45:38 PM
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 03:21:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:47:15 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/08/2024 08:05:18 PM
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 01:13:42 PM
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/29/2024 11:00:00 AM
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) • GlobeNewswire Inc. • 04/17/2024 01:10:00 PM
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 04/04/2024 01:15:00 PM
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:38:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 12:15:55 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM